Komboglyze: new hypoglycaemic combination

Bristol-Myers Squibb and AstraZeneca have launched Komboglyze, a fixed-dose combination of saxagliptin and metformin.

The combination tablet is taken twice daily at mealtimes.
The combination tablet is taken twice daily at mealtimes.

The tablets are licensed for use in patients with type II diabetes inadequately controlled by metformin alone and in those currently receiving the combination as separate tablets, or with insulin when insulin plus metformin is inadequate.

Komboglyze provides fixed doses of two hypoglycaemic agents with complementary mechanisms of action: saxagliptin, a dipeptidyl peptidase 4 inhibitor and metformin, a member of the biguanide class.

Greater HBA1c reduction than placebo

In a 12-week study, 160 patients whose blood glucose levels were not adequately controlled by metformin alone were randomised to receive placebo or saxagliptin 2.5mg twice daily in addition to metformin.

After 12 weeks, patients in the saxagliptin plus metformin group had a greater reduction in HbA1c than those in the placebo plus metformin group (0.6% vs 0.2%, p=NS).

Efficacious in combination with insulin

In another study, 455 patients with diabetes inadequately controlled by insulin or insulin plus metformin were randomised to receive saxagliptin 5mg or placebo as add-on therapy. After 24 weeks, significant improvements in HbA1c and postprandial glucose were observed in the saxagliptin add-on group compared with the placebo group.

View Komboglyze drug record

Further information: BMS/AstraZeneca

Follow MIMS on Twitter


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.